Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2011 Sep;31(9):2939-48.

Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis.

Author information

  • 1Department of Family and Preventive Medicine, University of California San Diego, 9500 Gilman Drive 0620, La Jolla, CA 92093-0620, USA. sbmohr75@gmail.com

Erratum in

  • Anticancer Res. 2011 Oct;31(10):3637.



Low serum levels of 25-hydroxyvitamin D [25(OH)D] have been associated with a high risk of breast cancer. Since publication of the most current meta-analysis of 25(OH)D and breast cancer risk, two new nested case-control studies have emerged.


A PubMed search for all case-control studies on risk of breast cancer by 25(OH)D concentration identified 11 eligible studies. Data from all 11 studies were combined in order to calculate the pooled odds ratio of the highest vs. lowest quantile of 25(OH)D across all studies.


The overall Peto odds ratio summarizing the estimated risk in the highest compared to the lowest quantile across all 11 studies was 0.61 (95% confidence interval 0.47, 0.80).


This study supports the hypothesis that higher serum 25(OH)D levels reduce the risk of breast cancer. According to the review of observational studies, a serum 25(OH)D level of 47 ng/ml was associated with a 50% lower risk of breast cancer.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk